1. Home
  2. ANIX vs SHIM Comparison

ANIX vs SHIM Comparison

Compare ANIX & SHIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

SELL

Current Price

$2.68

Market Cap

114.0M

Sector

Health Care

ML Signal

SELL

Logo Shimmick Corporation

SHIM

Shimmick Corporation

HOLD

Current Price

$2.58

Market Cap

128.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
SHIM
Founded
1982
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
128.6M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
ANIX
SHIM
Price
$2.68
$2.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
★ $9.75
$7.00
AVG Volume (30 Days)
★ 306.6K
120.3K
Earning Date
09-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
★ 81.95
EPS
★ N/A
N/A
Revenue
$210,000.00
★ $492,844,000.00
Revenue This Year
N/A
$1.41
Revenue Next Year
N/A
$20.36
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 2.63
52 Week Low
$2.32
$1.95
52 Week High
$5.46
$6.76

Technical Indicators

Market Signals
Indicator
ANIX
SHIM
Relative Strength Index (RSI) 39.55 29.67
Support Level $2.62 $2.45
Resistance Level $3.09 $4.09
Average True Range (ATR) 0.14 0.20
MACD 0.01 -0.03
Stochastic Oscillator 7.17 5.95

Price Performance

Historical Comparison
ANIX
SHIM

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About SHIM Shimmick Corporation

Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.

Share on Social Networks: